Arcturus Therapeutics (NASDAQ: ARCT) reported Q2 EPS of ($2.07), $0.07 better than the analyst estimate of ($2.14). Revenue for the quarter came in at $2 million versus the consensus estimate of $2.32 million.

• ARCT-021, Arcturus’ single shot STARR™ mRNA COVID vaccine, to begin multinational placebo-controlled Phase 3 efficacy study funded and sponsored by a global entity
• ARCT-154, Arcturus’ STARR™ mRNA vaccine candidate targeting COVID variants of concern, elicits robust neutralizing antibody titers against all variants tested in primates, including the Delta variant
• ARCT-154 to begin staged Phase 3 study in Vietnam; potential for EUA in December

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.